Alan Shaw, Ph.D.
President, CEO and Co-Founder
Alan Shaw, Ph.D., is President, Chief Executive Officer and Co-Founder of Calysta, and a member of the Board of Directors. He joined in 2012. Dr. Shaw is a veteran biotechnology entrepreneur and chemical industry executive, with more than 25 years experience building and leading technology companies. Before joining Calysta, he was a Founder of Codexis, and served for ten years as President, Chief Executive Officer and a director. Codexis is a developer of cost-advantaged processes for production of biobased chemicals and pharmaceuticals. During his tenure, Codexis completed an IPO and expanded from a startup to a global industrial biotechnology company with operations in the United States, Europe and Asia.
In 2010, Dr. Shaw received the Ernst and Young Entrepreneur® of the Year Award in the life sciences category for Northern California. He is a member of the Board of Directors of BIO and the Governing Board of the BIO Industrial and Environmental Section. He also serves as a biotechnology advisor to the governments of the United Kingdom and Malaysia, and is a frequent speaker at leading business and industry conferences.
Prior to Codexis, Dr. Shaw held senior operating and business development positions in the United Kingdom for Chiroscience Group plc and for the chemical and biopharmaceutical units of Clariant and BTP plc from 1994-99. For the previous 15 years, he held management and scientific leadership positions for Imperial Chemical Industries plc (ICI)/Zeneca, including Business Head, Fine Chemicals and Marketing Manager, European Sales. He holds a bachelor’s degree in chemistry from Teesside University and a Ph.D. in chemistry from the University of Durham, England. He is a Fellow of the Royal Society of Chemistry and a Fellow of the Chartered Institute of Marketing.
Vice President, Global Capital Projects
Graham Aylen, CEng.,is Vice President for Global Capital Projects at Calysta, and Managing Director of Calysta UK Limited. Mr. Aylen joined Calysta in 2014, working on the acquisition of Calysta AS in Norway. He currently focuses on the delivery of the small scale facility project in the United Kingdom and the commercialization of FeedKind™ protein.
Prior to joining Calysta, he held positions where he was responsible for the safe delivery of large scale capital projects in the fine chemical, pharmaceutical and biotechnology industries internationally with ICI, Zeneca, Avecia, Costain, GSK, Pfizer, Anglian Water and Codexis.
Mr. Aylen has also worked on professional committees developing policy with the UK and Malaysian Government and the IChemE.
Tomas Belloso, Ph.D.
Vice President, Regulatory Affairs
Tomas Belloso, Ph.D., joined Calysta as Vice President, Regulatory Affairs in 2016. He reports to Josh Silverman, Ph.D., Chief Product and Innovation Officer, and is responsible for the company’s regulatory and quality management programs and strategy.
Dr. Belloso has over a decade of senior regulatory, quality and product management experience in the feed and animal health industries. Before joining Calysta, he served as Regulatory Compliance Manager at the Feed Division of Wilbur-Ellis, a $3 billion international marketer and distributor of agricultural products, animal feed and specialty chemicals and ingredients. Prior to that, he held senior regulatory and product management positions at Royal Canin USA, a subsidiary of MARS, Inc., Nestle Purina, Monsanto and Elanco Animal Health.
He holds a Ph.D. in animal sciences and a Master’s degree in dairy sciences from the University of Florida, and a Bachelor’s degree in animal sciences from Universidad Rafael Urdaneta in Venezuela.
Vice President, Administration and General Counsel
Blake Campbell is Vice President, Administration and General Counsel for Calysta. He joined the company in 2016 as General Counsel and was named to his current position in 2017. He has responsibility for the company’s global legal strategy, planning and management and for administration. Prior to Calysta, Mr. Campbell served as General Counsel for Extend Health, Inc. and AlphaImpactRx, Inc. and as a senior attorney for several global law firms. Mr. Campbell has also served as a senior adviser to former California Senator and Governor Pete Wilson in Washington D.C. and Sacramento.
Mr. Campbell specializes in general corporate and finance matters and has extensive experience with project finance transactions, strategic and cross-border transactions, technology transfers, joint development and strategic IP licensing and portfolio management, mergers and acquisitions, initial public offerings, venture financings, executive compensation, board and committee support and governance, SEC/SOX/NASDAQ compliance and reporting and risk and litigation management.
Mr. Campbell holds a Bachelor of Arts from Stanford University and a JD from the University of California at Los Angeles.
Lori Giver, Ph.D.
Vice President, Research and Development
Lori Giver, Ph.D. was named Vice President, Research and Development in 2019. She joined Calysta in 2013 as Vice President, Biological Engineering. Previously, Dr. Giver was with Codexis, Inc., where she held a number of positions including Vice President of Systems Biology, Senior Director of Technology and Innovation, and Manager of Market Development. Prior to Codexis she was head of the Core Technology Group at Maxgyen, Inc.
Dr. Giver has focused her career on the directed evolution of nucleic acids, proteins and organisms. She has chaired a wide variety of conferences in the field including Enzyme Engineering XXI and Applications for Enzyme Technologies 2013. She is an author on numerous scientific publications and over 50 patents and patent applications. She received a Bachelor of Science degree in Molecular and Cell Biology from the University of California-Berkeley and Ph.D in Molecular Cell and Developmental Biology from Indiana University, Bloomington. Dr. Giver did her post-doctoral research at the California Institute of Technology in the laboratory of Dr. Frances Arnold, winner of the 2018 Nobel Prize in Chemistry.
Thomas JG Huot, Ph.D.
Chief Operating Officer
Thomas JG Huot, Ph.D. is Calysta’s Chief Operating Officer, leading global operations and corporate development activities. Additionally, Dr. Huot is responsible for corporate strategy and the commercialization of Calysta’s FeedKind® protein.
Dr. Huot brings more than 20 years of experience in research in biological sciences, venture investing, project financing and strategic partnerships, including a significant focus on industrial biotechnology, specialty chemicals and nutrition.
Prior to joining Calysta, he had previously been with VantagePoint Capital Partners, a global venture investor with a focus on energy innovation and technology that had more than $4bn under management. At VantagePoint, Dr. Huot was a Managing Director where he led the industrial biotechnology, food and agtech investing practice. Thereafter, Dr. Huot provided strategic advisory services to start-up companies and investment funds in the life sciences and nutrition sectors for Novalis Advisors LLC. It was here he first learned of Calysta and its pioneering sustainable, traceable protein, FeedKind, and after a year of advising the company with its commercialization and partnership strategy, in 2018, Calysta appointed Dr. Huot as Chief Business Officer.
Vice President and FeedKind® Product Manager
Allan LeBlanc was named Vice President and FeedKind® Product Manager in 2019. Mr. LeBlanc served as Senior Director and FeedKind Product Manager from 2017-2019, and as Product Manager, FeedKind® from 2015 to 2017. He joined Calysta in 2013 as Director of Corporate Development. He is responsible for global market and sales strategy for Calysta aquaculture nutritional products. He also provides market intelligence guiding future product development.
Prior to joining Calysta, Mr. LeBlanc worked in venture capital at Ballast Point Ventures, where he focused on the pharmaceutical and healthcare industry. He also has prior experience in investment banking at Raymond James, where he worked on both mergers and acquisitions and public equity offerings for airlines and environmental services companies. Mr. LeBlanc holds an MBA from the University of California-Berkeley’s Haas School of Business and a Bachelor of Science degree from the University of Florida.
Vice President, Business Development
Mr. Leong joined Calysta in 2015. He has responsibility for all business development strategy and program execution, including broadening the Calysta portfolio of strategic partnerships. He joined Calysta from Chemtex, an international technology and engineering organization, where he was the Executive Vice President responsible for worldwide marketing and business development. At Chemtex he played an integral role in building the renewable and sustainable products business, including launching and licensing Beta Renewables’ cellulosic ethanol technology.
Before joining Chemtex in 2008, Mr. Leong led the marketing and business development activities for the downstream petrochemical and chemical business of Aker Solutions, a global engineering and construction contractor. Over his 20 year tenure with the group, he was based in a number of international locations including Canada, Japan, Hong Kong, Singapore and the United Kingdom. He holds a bachelor of applied science degree in chemical engineering from the University of British Columbia and is a registered professional engineer in Canada.
Céline Schiff-Deb, Ph.D.
Senior Director, Product Innovation
Céline Schiff-Deb, Ph.D., joined Calysta in 2018 as Senior Director, Product Innovation. Dr. Schiff-Deb is leading the development of new sustainable products and applications to improve worldwide food security, leveraging Calysta’s proprietary gas fermentation platform.
Dr. Schiff-Deb has over fifteen years of experience in translating biotechnological innovations into commercial products in the areas of nutrition, cosmetic, chemicals, agriculture and drugs. After completing her Ph.D. in plant genetic and molecular biology, she worked from 2004-2011 in biotechnology consulting and strategy with Alcimed, a specialized consulting firm and as an independent consultant. Before joining Calysta, she worked from 2011-2017 in similar roles with biotechnology companies built around microbial platforms – Intrexon and Solazyme/TerraVia/Corbion.
A native of France, she holds a Master’s degree in agronomy from Agro Paris Tech and a Ph.D in plant genetics and molecular biology jointly from Agro Paris Tech and Stanford University.
Chief Financial Officer and Chief Sustainability Officer
Lynsey Wenger joined Calysta in 2016 as Chief Financial Officer and Chief Sustainability Officer. She is responsible for the company’s financial strategy, planning and management, and for expansion and implementation of Calysta’s long term sustainability strategy and programs. Ms. Wenger joined Calysta following a 16-year career with The Goldman Sachs Group, where she spent the greater part of the last decade specializing in global natural resources investment banking. She will have responsibility for the company’s financial strategy, planning and management, and for expansion and implementation of Calysta’s long term sustainability strategy and programs.
During Ms. Wenger’s career at Goldman Sachs, she managed and led investment banking activities in global natural resources ranging from international mergers and acquisitions and IPOs to multimillion-dollar equity transactions and debt placements. Her industry experience includes natural gas and electric utilities, power, renewables and alternative energy. Most recently, Ms. Wenger served as a Vice President in the Investment Banking Division, with responsibility for transactions in the corporate power and utility sectors. Previously, she served in the Americas Financing Group as Head of Investment Grade Power, Utility and Midstream Debt Capital Markets. Earlier in her career she held positions in Equity Derivative Sales in the United States and Australia.
Ms. Wenger holds an MBA from The Wharton School at the University of Pennsylvania and a Bachelor of Arts degree from Duke University.